Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
/
AVITA Medical
Create a narrative
AVITA Medical Community
NasdaqCM:RCEL Community
3
Narratives
written by author
0
Comments
on narratives written by author
40
Fair Values set
on narratives written by author
Community Investing Ideas
AVITA Medical
Popular
Undervalued
Overvalued
AVITA Medical
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
High Valuation Will Constrain Recovery Amid Regulatory And Cost Pressures
Key Takeaways Growing reimbursement challenges and payer pressure threaten revenue growth as sustaining premium pricing becomes increasingly difficult. Heavy reliance on RECELL and regulatory setbacks increase risk, while profitability and successful geographic expansion remain uncertain.
View narrative
US$3.00
FV
62.6% overvalued
intrinsic discount
20.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
AVITA Medical
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Aging Global Population And Tech Advances Will Transform Wound Care
Key Takeaways Accelerated adoption of new products and operational restructuring are likely to drive faster revenue growth, margin expansion, and earlier profitability than anticipated. Broad clinical utility, cost advantages, and alignment with biotech trends position AVITA for significant market expansion and potential acquisition interest.
View narrative
US$18.01
FV
72.9% undervalued
intrinsic discount
67.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
AVITA Medical
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Key Takeaways Expanded reimbursement clarity and favorable clinical outcomes are boosting provider confidence, leading to broader hospital adoption and increased revenue opportunities. New product launches and operational efficiencies diversify market reach and support improved margins, positioning AVITA for long-term profitability.
View narrative
US$9.60
FV
49.2% undervalued
intrinsic discount
42.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
RCEL
RCEL
AVITA Medical
Your Fair Value
US$
Current Price
US$4.88
86.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-52m
275m
2015
2018
2021
2024
2025
2027
2030
Revenue US$275.0m
Earnings US$57.6m
Advanced
Set Fair Value